Variable results after rituximab in neuromyelitis optica
- 1 June 2012
- journal article
- case report
- Published by Elsevier in Journal of the Neurological Sciences
- Vol. 317 (1-2), 103-105
- https://doi.org/10.1016/j.jns.2012.02.017
Abstract
No abstract availableKeywords
This publication has 12 references indexed in Scilit:
- Repeated Treatment With Rituximab Based on the Assessment of Peripheral Circulating Memory B Cells in Patients With Relapsing Neuromyelitis Optica Over 2 YearsArchives of Neurology, 2011
- Impact of rituximab on relapse rate and disability in neuromyelitis opticaMultiple Sclerosis Journal, 2011
- Increased T-cell immunity against aquaporin-4 and proteolipid protein in neuromyelitis opticaInternational Immunology, 2011
- Long-term follow-up of patients with neuromyelitis optica after repeated therapy with rituximabNeurology, 2011
- B‐cell activation influences T‐cell polarization and outcome of anti‐CD20 B‐cell depletion in central nervous system autoimmunityAnnals of Neurology, 2010
- Neuromyelitis optica in FranceNeurology, 2010
- Treatment of Neuromyelitis Optica With RituximabArchives of Neurology, 2008
- Variable responses to rituximab treatment in neuromyelitis optica (Devic’s disease)Neurological Sciences, 2007
- Revised diagnostic criteria for neuromyelitis opticaNeurology, 2006
- An open label study of the effects of rituximab in neuromyelitis opticaNeurology, 2005